Cipla has entered a phase of sideways consolidation after a decline of approximately 19.7 per cent from its all-time high, with support at Rs 1,366 and resistance at Rs 1,502. A decisive break and ...

You can now play an even larger range of puzzles on our site, every weekday and now also every Saturday. Check out our brand new puzzles below, from Hangman to Add Up and even a Jigsaw. Of course ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Return on investment - most recent fiscal year 16.16 ...

Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Dr Reddy's, Zydus Lifesciences,... Feb 19, 2025 19:23 Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue ...

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

Paytm gained 8%, with resistance at 770 and support at 710. Cipla is breaking out above 1500, support at 1450. Bajaj Finserv is weak, with downside levels at 1820-1800. Analyst suggestions include ...